egg-down

egg-downJH 4/70Not usedUsed INot use

The Efficacy and Safety of Selective H₁-Antihistamine versus Leukotriene Receptor Antagonist for Seasonal Allergic Rhinitis: A Meta-Analysis

<div><p>Background</p><p>Both selective H₁-antihistamine (SAH) and leukotriene receptor antagonist (LTRA) have been shown to be effective in treating patients with seasonal allergic rhinitis (SAR), but it is still uncertain which treatment option is optimal. This meta-analysis was aimed to compare the efficacy and safety of SAH and LTRA for SAR.</p><p>Materials and Methods</p><p>PubMed, EMBASE and the Cochrane Library were searched for all eligible studies that compared the efficacy and safety of SAH and LTRA for SAR up to September 7, 2014. The pooled mean difference (MD), odd ratios (ORs) and 95% confidence intervals (95% CIs) were calculated using a fixed- or random-effects model.</p><p>Results</p><p>Nine studies with 5781 SAR patients were included. The results showed that SAH is superior to LTRA in terms of the daytime eye symptoms score (DESS) and composite symptoms score (CSS) for SAR (MD = 0.06, 95% CI, 0.03 to 0.10, <i>P</i> = 0.000, <i>I</i>² = 99%; MD = 0.03, 95% CI, 0.01 to 0.05, <i>P</i> = 0.010, <i>I</i>² = 98%), whereas LTRA overmatched SAH with respect to the night-time symptoms score (NSS) (MD = −0.04, 95% CI, −0.05 to −0.02, <i>P</i> = 0.000, <i>I</i>² = 97%). Additionally, the results of subgroup analysis indicated that the dose, duration and gender of the patients might impact the comparisons of the effects of SAH and LTRA on their efficacy for SAR.</p><p>Conclusion</p><p>This meta-analysis suggested that SAH and LTRA have similar effects and safety for SAR, but SAH is more appropriate for daytime nasal symptoms (congestion, rhinorrhea, pruritus and sneezing), while LTRA is better suited for nighttime symptoms (difficulty going to sleep, nighttime awakenings, and nasal congestion on awakening), respectively. Meanwhile, the dose, duration and gender of patients may influence the anti-SAR effects of SAH and LTRA.</p></div

Subgroup Analysis for the Effective and Safety of Leukotriene antagonist versus Selective H₁ antihistamine for Seasonal allergic rhinitis.

<p>LTRA, Leukotriene antagonist; SAH, Selective antihistamine; DNSS, Daytime nasal symptoms score; DESS, Daytime eye symptoms score; CSS, Composite symptoms score; NSS, Night-time symptoms score; RQOLS, Rhinoconjunctivitis quality-of-Life score.</p><p>Subgroup Analysis for the Effective and Safety of Leukotriene antagonist versus Selective H₁ antihistamine for Seasonal allergic rhinitis.</p

The screening process of studies.

<p>The screening process of studies.</p

Characteristics of Studies Included in the Meta-analysis.

<p>AR, allergic rhinitis;AC, allergic conjunctivitis; DNSS, daytime nasal symptoms score; DESS, daytime eye symptoms score; CSS, composite symptoms score; NSS, nighttime symptoms score; RQLQ, rhinoconjunctivitis quality-of-life scores.</p><p>Characteristics of Studies Included in the Meta-analysis.</p

Upgrading of Bio-oil over Bifunctional Catalysts in Supercritical Monoalcohols

In this paper, bio-oil from fast pyrolysis of Pinus sylvestris L. was upgraded over supported noble metal catalysts in supercritical monoalcohols under a hydrogen atmosphere. Esterification, cracking (both alcoholysis and hydrolysis), hydrogenation, along with acetalization, isomerization, and other reactions were combined during the upgrading process. The product analysis showed that processing in ethanol over Pt/SO₄^2–/ZrO₂/SBA-15 had a good upgrading performance. The removal of acids and aldehydes and the decrease of ketones, phenols, sugars, and polycyclic aromatic hydrocarbons were achieved. Meanwhile, esters became dominant in upgraded oil. The effects of solvents, noble metal catalysts, and catalyst supports had been briefly discussed. Pretreatment tests suggested that the presented upgrading process can be applied to the whole bio-oil without fractionation. As a result, an effective solvent recovery and a post-water-removal process will be required for the application of upgraded oil

Additional file 1 of Identification of crucial lncRNAs and mRNAs in liver regeneration after portal vein ligation through weighted gene correlation network analysis

Additional file 1: Supplementary Figure S1. DEmRNAs and DElncRNAs probesets between control group and PVL group. (A) There were 3686 DEmRNAs probesets between control group and PVL day 1 (p-value < 0.05 and FC ≥ 2.0), 2965 DEmRNAs probesets between control group and PVL day 7, 3570 DEmRNAs probesets between control group and PVL day 14. (B) There were 2485 DElncRNAs probesets between control group and PVL day 1 (p-value < 0.05 and FC ≥ 2.0), 2391 DElncRNAs probesets between control group and PVL day 7, 2694 DElncRNAs probesets between control group and PVL day 14

Additional file 2 of Identification of crucial lncRNAs and mRNAs in liver regeneration after portal vein ligation through weighted gene correlation network analysis

Additional file 2: Supplementary Figure S2. Hierarchical cluster analysis. (A) Hierarchical cluster analysis showed the expression variations of these hub mRNAs in lobe-pbs at different time points. (B) Hierarchical cluster analysis showed the expression variations of these hub lncRNAs in lobe-pbs at different time points

Associations between the Genetic Polymorphisms of Osteopontin Promoter and Susceptibility to Cancer in Chinese Population: A Meta-Analysis

<div><p>Background and Aim</p><p>Several studies have been conducted to examine the associations between osteopontin (OPN) promoter gene <i>SPP1</i> polymorphisms with human cancers in Chinese population, but the results remain inconsistent. The aim of this meta-analysis is to clarify the associations between <i>SPP1</i> polymorphisms and cancer susceptibility.</p><p>Methods</p><p>All eligible case-control studies published up to March 2015 were identified by searching PubMed, Web of Science, Embase, and Cochrane Library without language restrictions. Pooled odds ratio (OR) and 95% confidence interval (95% CI) were calculated using fixed- or random-effect model.</p><p>Results</p><p>A total of 11 case-control studies were included; of those, there were eleven studies (3130 cases and 3828 controls) for -443T>C polymorphism, ten studies (3019 cases and 3615 controls) for -156G>GG polymorphism, eight studies (2258 cases and 2846 controls) for -66T>G polymorphism. Overall, no evidence indicated that the -443 T>C polymorphism was associated with cancer risk (OR = 0.93, 95%CI 0.62–1.38 for dominant model, OR = 1.06, 95%CI 0.73–1.55 for recessive model, OR = 0.88, 95%CI 0.62–1.26 for CT vs TT model, OR = 1.03, 95%CI 0.61–1.73 for CC vs TT model). While, a significantly increase risk was found for -156 G>GG polymorphism (OR = 1.22, 95%CI 1.10–1.35 for dominant model, OR = 1.25, 95%CI 1.10–1.41 for recessive model, OR = 1.18, 95%CI 1.06–1.32 for GGG vs GG model, OR = 1.35, 95%CI 1.09–1.68 for GGGG vs GG model). For -66T>G polymorphism, we found a decrease risk of cancer (OR = 0.84, 95% CI 0.71–0.98 for dominant model), but this result changed (OR = 0.93, 95% CI 0.77–1.12 for dominant model) when we excluded a study.</p><p>Conclusion</p><p>This meta-analysis suggests that in Chinese population the -156G>GG polymorphism of <i>SPP1</i> might be a risk factor for human cancers, while -443T>C mutation is not associated with cancer risk. For -66T>G polymorphism, it may be a protective factor for human cancers.</p></div

Additional file 3 of Identification of crucial lncRNAs and mRNAs in liver regeneration after portal vein ligation through weighted gene correlation network analysis

Additional file 3: Table S1